SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, LLC, bioMérieux’s molecular biology affiliate, announced today that it has commenced clinical and analytical studies to evaluate the company’s ...

MARCY L’ÉTOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) ...

A multicenter evaluation of BioFire RP2.1 for the detection of SARS-CoV-2 in 524 nasopharyngeal swab samples was conducted by Berry et al. In this study, one or more targets on the panel were detected ...

Conventional routine PCR testing for gastrointestinal infections is generally based on pathogen related panels specifically requested by clinicians and can be erroneous and time consuming. The BioFire ...

Falsey AR, Branche AR, Croft DP, et al. Real-Life Assessment of BioFire FilmArray® Pneumonia Panel in Adults Hospitalized with Respiratory Illness. J Infect Dis. 2023 Jun 27:jiad221. doi: ...

SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., announced today the FDA clearance of its FilmArray Blood Culture Identification (BCID) Panel. To date, the 27-target panel is the most ...

June 7, 2013 -- BioFire Diagnostics Inc. announced today that it obtained the CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices for its FilmArray Blood Culture ...

Salt Lake City, UT – BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray system.

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology ...